Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Obesity × Dalteparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Classical hematology 1

Conditions

Venous Thromboembolism 3 Neoplasms 3 Venous Thrombosis 2 Thrombosis 2 Thromboembolism 1 Pulmonary Embolism 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Obesity 1 Multiple Myeloma 1 Gliosarcoma 1 Glioblastoma 1 Embolism and Thrombosis 1 Embolism 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1

Interventions

Vitamin D 2 Tirzepatide 2 licogliflozin 1 indole-3-carbinol 1 bupropion hydrochloride, naltrexone hydrochoride drug combination 1 Tablets 1 Specimen Handling 1 Resistance Training 1 Progestins 1 Pregabalin 1 Orlistat 1 Organizational Objectives 1 Omeprazole 1 Observation 1 Naltrexone 1 Metformin 1 Ketorolac 1 Exergaming 1 Exercise 1 Exenatide 1 Diet, Plant-Based 1 Dexmedetomidine 1 Dalteparin 1 Counseling 1 Cholecalciferol 1 Calcium Citrate 1 Calcium Carbonate 1 Calcitriol 1 CKD732 1 Bupropion 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03297359 2024-01-23

WAVe

Ottawa Hospital Research Institute

Phase 2 Terminated

Classical hematologyOther

Neoplasms, Obesity, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡